Cargando…

Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency

Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Method...

Descripción completa

Detalles Bibliográficos
Autores principales: Pieniawska-Śmiech, Karolina, Kuraszewicz, Anna, Sado, Joanna, Śmiech, Karol, Lewandowicz-Uszyńska, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584568/
https://www.ncbi.nlm.nih.gov/pubmed/34768630
http://dx.doi.org/10.3390/jcm10215111
_version_ 1784597480880472064
author Pieniawska-Śmiech, Karolina
Kuraszewicz, Anna
Sado, Joanna
Śmiech, Karol
Lewandowicz-Uszyńska, Aleksandra
author_facet Pieniawska-Śmiech, Karolina
Kuraszewicz, Anna
Sado, Joanna
Śmiech, Karol
Lewandowicz-Uszyńska, Aleksandra
author_sort Pieniawska-Śmiech, Karolina
collection PubMed
description Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Methods: In this retrospective study, medical records of 99 patients aged 0–18 were evaluated. The patients were divided into three groups: PID group (68.69%), control group (19.19%) and patients with ongoing or previous paediatric inflammatory multisystem syndrome (12.12%). Data such as morbidity, clinical outcome, and IgG anti-SARS-CoV-2 antibody titres were assessed. Results: A confirmed diagnosis of SARS-CoV-2 infection has been established in 26.47% of patients with PID. Among patients with PID infected with SARS-CoV-2, only three cases were hospitalised. Mortality in the PID group was 0%. Throughout an observation period of 1 year, 47.06% of patients with PID were tested positive for the anti-SARS-CoV-2 antibody. Conclusions: In the study group, in most cases the disease had a mild and self-limiting course. Remarkably, even though IgG deficiency was the most prevalent form of PID in the study group, the patients were able to respond satisfactorily to the infection in terms of anti-SARS-CoV-2 IgG.
format Online
Article
Text
id pubmed-8584568
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85845682021-11-12 Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency Pieniawska-Śmiech, Karolina Kuraszewicz, Anna Sado, Joanna Śmiech, Karol Lewandowicz-Uszyńska, Aleksandra J Clin Med Article Background: Data regarding the course of SARS-CoV-2 infection in children with primary immunodeficiency (PID) is insufficient. The purpose of the study was to evaluate the morbidity and clinical course of COVID-19 and the ability to produce anti-SARS-CoV-2 IgG antibodies in children with PID. Methods: In this retrospective study, medical records of 99 patients aged 0–18 were evaluated. The patients were divided into three groups: PID group (68.69%), control group (19.19%) and patients with ongoing or previous paediatric inflammatory multisystem syndrome (12.12%). Data such as morbidity, clinical outcome, and IgG anti-SARS-CoV-2 antibody titres were assessed. Results: A confirmed diagnosis of SARS-CoV-2 infection has been established in 26.47% of patients with PID. Among patients with PID infected with SARS-CoV-2, only three cases were hospitalised. Mortality in the PID group was 0%. Throughout an observation period of 1 year, 47.06% of patients with PID were tested positive for the anti-SARS-CoV-2 antibody. Conclusions: In the study group, in most cases the disease had a mild and self-limiting course. Remarkably, even though IgG deficiency was the most prevalent form of PID in the study group, the patients were able to respond satisfactorily to the infection in terms of anti-SARS-CoV-2 IgG. MDPI 2021-10-30 /pmc/articles/PMC8584568/ /pubmed/34768630 http://dx.doi.org/10.3390/jcm10215111 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Pieniawska-Śmiech, Karolina
Kuraszewicz, Anna
Sado, Joanna
Śmiech, Karol
Lewandowicz-Uszyńska, Aleksandra
Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_full Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_fullStr Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_full_unstemmed Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_short Assessment of COVID-19 Incidence and the Ability to Synthesise Anti-SARS-CoV-2 Antibodies of Paediatric Patients with Primary Immunodeficiency
title_sort assessment of covid-19 incidence and the ability to synthesise anti-sars-cov-2 antibodies of paediatric patients with primary immunodeficiency
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584568/
https://www.ncbi.nlm.nih.gov/pubmed/34768630
http://dx.doi.org/10.3390/jcm10215111
work_keys_str_mv AT pieniawskasmiechkarolina assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency
AT kuraszewiczanna assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency
AT sadojoanna assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency
AT smiechkarol assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency
AT lewandowiczuszynskaaleksandra assessmentofcovid19incidenceandtheabilitytosynthesiseantisarscov2antibodiesofpaediatricpatientswithprimaryimmunodeficiency